However, it has been suggested that the prognostic factors for EBV-associated tumors may include age, EBV gene expression, tumor mutation burden and immune infiltration.71,72 Particularly, EBV was found to be more frequent in the MSS/TP53 + subtype of EBVaGC, with significant enrichment of PIK3CA and ARID1A mutations, and increased immune infiltrates.73 In this study, we showed that DNA tumor viruses could markedly promote tumor progression by inhibiting PERK activity. The gene discussed is ARID1A; the disease is neoplasm.